Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or alzheimer's disease

Journal of Alzheimer's Disease

Volumn 35, Issue 4, 2013, Pages 789-797

  Claxton, Amy ^a,b   Baker, Laura D ^c   Wilkinson, Charles W ^a,b   Trittschuh, Emily H ^a,b   Chapman, Darla ^a,b   Watson, G Stennis ^a,b   Cholerton, Brenna ^a,b   Plymate, Stephen R ^a,b   Arbuckle, Matthew ^a   Craft, Suzanne ^c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; insulin; intranasal drug administration; mild cognitive impairment; randomized clinical trials

Indexed keywords

APOENZYME; INSULIN; PLACEBO; RECOMBINANT HUMAN INSULIN;

ADULT; AGED; ALZHEIMER DISEASE; ANALYSIS OF COVARIANCE; CONTROLLED STUDY; DRUG DELIVERY DEVICE; FEMALE; GENETIC DIFFERENCE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; REVIEW; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84878864610     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122308     Document Type: Review

References (43)

1. Havrankova J, Roth J, BrownsteinM(1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272, 827-829.
2. Marks JL, Porte D Jr., Stahl WL, Baskin DG (1990) Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology 127, 3234-3236.
3. Porte D Jr., Baskin DG, Schwartz MW(2005) Insulin signaling in the central nervous system: A critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 54, 1264-1276.
4. Schwartz MW, Figlewicz DF, Kahn SE, Baskin DG, Greenwood MR, Porte D Jr. (1990) Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 11, 467-472.
5. Cole AR, Astell A, Green C, Sutherland C (2007) Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 31, 1046-1063.
6. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21, 2561-2570.
7. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
8. Hoyer S, Lee SK, Loffler T, Schliebs R (2000) Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920, 256-258.
9. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
10. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 36, 811-822.
11. Zhao WQ, Townsend M (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792, 482-496.
12. Park CR, Seeley RJ, Craft S, Woods SC (2000) Intracerebroventricular insulin enhances memory in a passiveavoidance task. Physiol Behav 68, 509-514.
13. Benedict C, Frey WH 2nd, Schioth HB, Schultes B, Born J, Hallschmid M (2011) Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 46, 112-115.
14. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5, 514-516.
15. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13, 323-331.
16. Reger MA,Watson GS, Green PS,Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
17. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69, 29-38.
18. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364.
19. Clegg DJ, Riedy CA, Smith KA, Benoit SC,Woods SC (2003) Differential sensitivity to central leptin and insulin in male and female rats. Diabetes 52, 682-687.
20. Hallschmid M, Benedict C, Schultes B, Fehm HL, Born J, Kern W(2004) Intranasal insulin reduces body fat in men but not in women. Diabetes 53, 3024-3029.
21. Benedict C,Kern W, Schultes B, Born J, Hallschmid M(2008) Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 93, 1339-1344.
22. Krug R, Benedict C, Born J, Hallschmid M (2010) Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 95, E468-E472.
23. Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, Mulnard RA, Thomas RG, Thal LJ (2003) Steroid-induced elevation of glucose in Alzheimer's disease: Relationship to gender, apolipoprotein E genotype and cognition. Psychoneuroendocrinology 28, 113-120.
24. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K (1999) Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70, 146-152.
25. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.
26. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101, 284-289.
27. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, Rocca WA (2008) The Mayo Clinic Study of Aging: Design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58-69.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM(1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944.
29. Craft S, Asthana S, Newcomer JW,Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56, 1135-1140.
30. Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y, Luby J, Dagogo-Jack A, Alderson A (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17, 123-130.
31. Clark CM, Ewbank DC (1996) Performance of the dementia severity rating scale: A caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord 10, 31-39.
32. GalaskoD, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer'sDisease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S33-S39.
33. Kilpatrick C, Murrie V, Cook M, Andrewes D, Desmond P, Hopper J (1997) Degree of left hippocampal atrophy correlates with severity of neuropsychological deficits. Seizure 6, 213-218.
34. Tulving E, Kapur S, Craik FI, Moscovitch M, Houle S (1994) Hemispheric encoding/retrieval asymmetry in episodic memory: Positron emission tomography findings. Proc Natl Acad Sci U S A 91, 2016-2020.
35. Jensen MD, Nielsen S, Gupta N, Basu R, Rizza RA (2012) Insulin clearance is different in men and women. Metabolism 61, 525-530.
36. Vistisen D, Witte DR, Tabak AG, Brunner EJ, Kivimaki M, Faerch K (2012) Sex differences in glucose and insulin trajectories prior to diabetes diagnosis: The whitehall II study. [published online ahead of print Sept 16, 2012] Acta Diabetol, doi: 10.1007/s00592-012-0429-7
37. Cholerton B, Baker LD, Trittschuh EH, Crane PK, Larson EB, Arbuckle M, Saucedo HH, McCurry SM, Bowen JD, McCormick WC, Craft S (2012) Insulin and sex interactions in older adults with mild cognitive impairment. J Alzheimers Dis 31, 401-410.
38. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903, 222-228.
39. Profenno LA, Faraone SV (2008) Diabetes and overweight associate with non-APOE4 genotype in an Alzheimer's disease population. Am J Med Genet B Neuropsychiatr Genet 147B, 822-829.
40. Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T, Holtzman DM, Morris JC (2012) Exercise engagement as a moderator of the effects of APOE Genotype on Amyloid Deposition. Arch Neurol 69, 636-643.
41. VanFossenBT,Watson GS, Baker LD, RhoadsKW, Cholerton BA, Reger MA, Plymate SR, Schellenberg G, Craft S (2010) Statin users without an APOE-epsilon4 allele have increased insulin resistance. J Alzheimers Dis 19, 1149-1153.
42. Nebes RD, Pollock BG, Perera S, Halligan EM, Saxton JA (2012) The greater sensitivity of elderly APOE epsilon4 carriers to anticholinergic medications is independent of cerebrovascular disease risk. Am J Geriatr Pharmacother 10, 185-192.
43. Hallschmid M, Benedict C, Schultes B, Born J,Kern W(2008) Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 32, 275-282.